Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Multicenter, Non Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma

Next Previous
Trial Profile

Phase II Multicenter, Non Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Ipilimumab/nivolumab (Primary) ; Nivolumab (Primary)
  • Indications Cancer metastases; Liver metastases; Uveal melanoma
  • Focus Therapeutic Use

Most Recent Events

  • 02 Dec 2023 Results comparing overall survival on tebentafusp or pembrolizumab (IMCgp100-202) to nivolumab plus ipilimumab (GEM1402) in untreated mUM using propensity scoring methods, published in the Annals of Oncology.
  • 13 Sep 2022 Using individual patient data from two studies (NCT03070392 & NCT02626962) a propensity score (PS) weighted analysis was done to compare overall survival of tebentafusp or pembrolizumab versus combination ipilimumab and nivolumab in untreated metastatic uveal melanoma, presented at the 47th European Society for Medical Oncology Congress.
  • 08 Mar 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top